AlphAIAlphAI — Financial news for AI agents
investing.comOCT 281 min read$BLCO

Bausch + Lomb earnings beat by $0.13, revenue topped estimates

Bausch + Lomb (BLCO) reported Q3 EPS of $0.34, beating estimates by $0.13, with revenue of $1.38B, slightly above expectations. The company forecasts FY 2026 revenue of $5.45B-$5.55B, below the analyst consensus of $5.49B. BLCO's stock is up 4.20% in the last 3 months and 13.90% in the last 12 months.

Original reporting
investing.com
Published Oct 28, 2026, 11:06 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 11:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BLCO
Bullish
high confidence
Mentioned
$BLCO
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BLCOBullishMed
01

Why it matters

The earnings surprise and guidance raise expectations for near‑term price appreciation, though sector dynamics and cost pressures remain considerations.

02

Market read

Earnings beat and guidance upgrade are primary catalysts for BLCO, offering a medium‑term trading opportunity.

03

What to watch

Potential headwinds from raw material costs and competitive pricing pressure.

Relevance 7/10Novelty 7/10Timing: post-market reaction

Background

Bausch + Lomb (NYSE: BLCO) is a leading eye health company. The article provides its latest quarterly earnings and FY guidance.

Company-level read

Ticker impact

$BLCOBullishHigh confidence
Context

Bausch + Lomb reported Q3 EPS of $0.34, beating estimates by $0.13 and posted FY2026 revenue guidance of $5.45B-$5.55B.

Expected impact

likely upward pressure as investors price in the beat and higher guidance

Evidence & confidence

The surprise EPS beat and revenue outlook exceed consensus, providing a clear catalyst for buying interest.

Market effects

Sector

May lift other eye‑care and consumer health stocks as the segment shows resilience.

Regional

Positive for US healthcare equities, limited broader market effect.

Global

Low; impact confined to sector and related peers.

Counterpoint

What could challenge this read

If guidance falls short of long‑term growth expectations, the beat may be short‑lived.

Key entities

  • company
    Bausch + Lomb

    Eye health products manufacturer reporting Q3 results.

Read at source← All news

StoryBausch + Lomb posts Q3 profit and lifts full‑year 2026 guidance

Also covered by

6 outlets

Related articles

OCT 28
$BLCOHighAI 9/10

Why is Bausch + Lomb stock surging today?

Bausch + Lomb (BLCO) stock rose 7.3% after Q3 2026 earnings beat estimates, with adjusted EPS of $0.34 vs. $0.21 expected, and revenue of $1.375B, up 7% YoY. The company raised full-year guidance for the third time, citing growth across all segments and improved profitability. The stock reached a 52-week high of $19.09.

investing.com2 min
OCT 28
$BLCOMedAI 8/10

Bausch + Lomb (BLCO) Q3 2026 Earnings Call Transcript

Bausch + Lomb (BLCO) reported Q3 2026 earnings with 8% revenue growth to $1.375B, 34% adjusted EBITDA increase, and 23.6% margin. All segments grew: Pharmaceuticals +11%, Surgical +9%, Vision Care +6%. The company reduced net leverage to 4.1x and remains confident in meeting its 3-year plan targets.

finance.yahoo.com2 min
OCT 28
$BLCOHighAI 8/10

Bausch + Lomb Posts 7% Revenue Growth, Raises 2026 Guidance

Bausch + Lomb reported Q3 2026 revenue of $1.375B, up 7% YoY, and net income of $32M. Adjusted EBITDA was $325M, and adjusted diluted EPS was $0.34. The company raised full-year revenue guidance to $5.45B–$5.55B and adjusted EBITDA guidance to $1.09B–$1.14B. All business segments grew, with notable increases in MIEBO and LUMIFY revenues.

tradingview.com1 min